{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-117080","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2026-10-20T10:35:29+00:00","discovered_at":"2026-10-20T10:40:00.228813+00:00","generated_at":"2026-10-20T10:40:06.282361+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Quoin publishes peer-reviewed QRX003 paper; pediatric Netherton case clear at 21 months","bullets":["Peer-reviewed paper in Dermatology and Therapy, published online Oct 13, 2026, introduces QRX003 and reports Prof. Alan Irvine's pediatric compassionate-use case.","Pediatric Netherton patient on once-daily whole-body QRX003 improved IGA from 4 (severe) to 1 at six weeks and WI-NRS itch from 5 to 1.","By eight months IGA was 0 (clear) and WI-NRS 0; over 21 months mostly IGA 0, off antihistamines, glucocorticoids and antivirals, no treatment-related adverse events.","Phase 2/3 CL-QRX003-004 interim: 4 of 6 (66.7%) met primary IGA endpoint (p=0.0087 vs alpha 0.0215); full 20-patient enrollment targeted by end-2026, topline Q2 2027.","Case is first pediatric use of QRX003 and longest continuous exposure to date; authors caution single-patient observations require trial confirmation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-117080","json":"https://secwatch.observer/filing/0001104659-26-117080.json","markdown":"https://secwatch.observer/filing/0001104659-26-117080.md","text":"https://secwatch.observer/filing/0001104659-26-117080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926117080/0001104659-26-117080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926117080/tm2627720d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T10:40:06.282361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}